Botulinum toxin type A reduces inflammatory hypernociception induced by arthritis in the temporomadibular joint of rats

Author(s)

Manuel Munoz Lora, Victor Ricardo ; Clemente-Napimoga, Juliana Trindade ; Abdalla, Henrique Ballassini ; Macedo, Cristina Gomes ; Canales, Giancarlo de la Torre ; Rizzatti Barbosa, Celia Marisa

• Document type: Journal article
• Source: Toxicon; v. 129, p. 52-57, APR 2017.
• Web of Science Citations: 11

Abstract

Objective: This study aimed to investigate the antinociceptive effects of Botulinum toxin type A (BoNT-A) on persistent inflammatory hypernociception induced by arthritis in the temporomandibular joint (TMJ) of rats. Material and methods: Wistar rats were induced to persistent inflammatory hypernociception in the left TMJ. Then, animals were treated with intra-TMJ injections of BoNT-A, using doses of 3.5, 7 and 14 U/kg. Saline was used as control group. Behavioral tests were applied to evaluated the effect of BoNT-A in the inflammatory hypernociception. After that, animals were euthanized and samples from peri-articular tissues and trigeminal ganglia were obtained for further analyses. Results: BoNT-A reduced the persistent inflammatory hypernociception induced by arthritis in the TMJ of rats. BoNT-A significantly reduced the peripheral release of the neurotransmitters Substance P and Calcitonin gene related peptide; and the pro-inflammatory cytokine IL-10. Otherwise, BoNT-A had no effect in the peripheral release of glutamate and the cytokine TNF-alpha. Conclusion: These results demonstrate that intra-articular injection of BoNT-A reduces the albumin induced arthritis persistent hypernociception in TMJ of rats by peripheral inhibition of neuropeptides release. 2017 Elsevier Ltd. All rights reserved. (AU)

• FAPESP's process: 14/15863-7 - Comparison of conventional and BontA treatments in patients with myogenic temporomandibular disorders and chronic pain
• Grantee: Celia Marisa Rizzatti Barbosa
• Support Opportunities: Regular Research Grants